Zyvox

Zyvox for oral suspension is supplied as an orange-flavored granule/powder for constitution into a suspension for oral administration. Following constitution, each 5 mL contains 100 mg of linezolid. Inactive ingredients are 

Linezohd (Zyvox) is an oxazolidinone, a tive-membered heterocychc ring that forms the core of the hnezohd structure. The approval of hnezohd by the FDA in 2000 marked the first new structural class of antibacterial introduced into medical practice in the United States in 40 years. It is notable for its activity against methicillin-resistant Staph aureus, MRSA, and vancomycin-resistant Enterococcus faecium, VRE. It is bacteriostatic rather than bactericidal but finds significant use in patients with an intact immune system. Like several other classes of antibacterials, linezolid is an inhibitor of protein synthesis. It interacts specifically with the RNA component of a bacterial ribosome subunit to prevent initiation of protein synthesis. 

Linezolid (Zyvox) Pharmacia/Upjohn (Pfizer) Launched 2000 

Linezolid (Zyvox) is the first of a new classification, an oxazolidinone, that acts by bindingto a site on a specific ribosomal RNA and preventing the formation of a component necessary for the bacteria to replicate It is 

Linezolid (Zyvox) Used as a last generation against gram- 

Linezolid (Zyvox ) Pharmacia/Pfizer Antibacterial agent Launched 2000 

USAN- Linezolid Trade Name Zyvox Pharmacia Launched 2000 M.W. 337.35 

Aztreonam (Azactam) Clindamycin (Cleocin, Cleocin-T, others) Fosfomycin (Monurol) Linezolid (Zyvox) Metronidazole (Flagyl, MetroGel) 

Netilmicin (Netromycin) Erythromycin lactobionate (Erythrocin) Tetracycline (Achromycin V, others) Linezolid (Zyvox) 

The remarkable capacity of S. aureus to develop resistance to antibiotics is no more clearly illustrated than its recently reported success against linezolid (Zyvox ). Linezoid is the first entirely new type of antibiotic (oxazolidinones) introduced in 35 years. The FDA approved it in April 2000 for the treatment of several infections including resistant strains of S. aureus. Flowever, it took only slightly more than a year for resistance to manifest itself. In the summer of 2001, the first report of staph resistance to the new antibiotic was observed in an 85-year-old man undergoing dialysis. 

---